Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Accumulated Expenses (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Accumulated Expenses for 9 consecutive years, with $941000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 89.85% year-over-year to $941000.0, compared with a TTM value of $941000.0 through Dec 2025, down 89.85%, and an annual FY2025 reading of $941000.0, down 89.85% over the prior year.
  • Accumulated Expenses was $941000.0 for Q4 2025 at VYNE Therapeutics, up from $819000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $13.5 million in Q1 2021 and bottomed at $736000.0 in Q2 2024.
  • Average Accumulated Expenses over 5 years is $3.9 million, with a median of $3.3 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 125.1% in 2024, then tumbled 89.85% in 2025.
  • Year by year, Accumulated Expenses stood at $2.8 million in 2021, then fell by 13.81% to $2.4 million in 2022, then surged by 73.65% to $4.1 million in 2023, then skyrocketed by 125.1% to $9.3 million in 2024, then crashed by 89.85% to $941000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for VYNE at $941000.0 in Q4 2025, $819000.0 in Q2 2025, and $6.9 million in Q1 2025.